Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (NASDAQ:TNYA) reported interim MyPEAK-1 Phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated HCM.
Seven patients received TN-201; six were evaluable and showed reductions in left ventricular mass, improved NYHA class, KCCQ scores, exercise capacity, and favorable biomarker trends. TN-201 was generally well tolerated with no dose-limiting toxicities. The EMA granted PRIME designation and the FDA accepted a pediatric indication into the RDEP process. Enrollment at 6E13 vg/kg continues and Tenaya plans further long-term data in 2H 2026 and regulatory updates by year end.
Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Management will host a webcast at 8:00 a.m. ET, accessible via the Investors section under “Events & Presentations,” with an archived replay available for about 30 days.
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
CEO Faraz Ali is scheduled to present on Thursday, June 4, 2026, at 3:10 p.m. ET, with live and archived webcasts available via Tenaya’s investor website.
Tenaya Therapeutics (NASDAQ:TNYA) reported positive interim data from Cohorts 1 and 2 of the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC.
All six treated adults showed meaningful PVC burden reductions (mean 64%) with TN-401 well tolerated at 3E13 and 6E13 vg/kg and supported by biopsy evidence of cardiac transduction. TN-401 also received EMA PRIME designation.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q1 2026 results and a business update on May 6, 2026. Cash and cash equivalents were $80.9M as of March 31, 2026, and Tenaya expects funding into the second half of 2027 including a $10.0M upfront from an Alnylam collaboration. The company highlighted upcoming clinical readouts for TN-201 and TN-401, preclinical TN-301 DMD data, FDA Rare Pediatric and Orphan designations for TN-301, and expanded research with Alnylam with milestones up to $1.1B.
Tenaya Therapeutics (NASDAQ: TNYA) announced acceptance of multiple abstracts for ASGCT 2026, including a late-breaking oral presentation with new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial of TN-401 for PKP2-associated ARVC. The presentation will include one-year Cohort 1 results and early Cohort 2 safety, biopsy and efficacy data on May 15, 2026. Tenaya will also present two posters and plans a webcast conference call to review RIDGE-1 data.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q4 and full-year 2025 results, highlighted early clinical readouts for lead gene therapies TN-201 and TN-401, preclinical TN-301 data in DMD models, a multi-target research collaboration with Alnylam, and a December public offering raising net proceeds of $55.8M.
The company reported cash and marketable securities of $100.5M at year-end and expects resources plus an anticipated Alnylam upfront payment to fund operations into the second half of 2027.
Tenaya Therapeutics (NASDAQ: TNYA) presented preclinical data at MDA 2026 showing its selective HDAC6 inhibitor TN-301 improved muscle performance and corrected DMD cardiomyopathy drivers in vitro and in vivo. TN-301 restored mdx mouse muscle function to wild-type levels at 3 mg/kg and corrected human DMD iPSC-cardiomyocyte defects. A Phase 1 in healthy adults showed TN-301 was generally well tolerated without serious adverse events or dose-limiting toxicities. Tenaya plans to advance TN-301 toward Phase 2 clinical development, with HFpEF and DMD among prioritized indications.
Tenaya Therapeutics (NASDAQ: TNYA) entered a research collaboration with Alnylam (NASDAQ: ALNY) on March 5, 2026 to identify and validate up to 15 gene targets for cardiovascular disease.
Tenaya will receive up to $10 million upfront plus reimbursed costs over a two-year validation term and may receive up to $1.13 billion in development and commercial milestone payments if targets lead to approved therapeutics; Alnylam will handle development and commercialization.
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026. CEO Faraz Ali will join a fireside chat on March 9, 2026 at 1:00 pm ET. A live webcast will stream via the company Investors site, with an archived replay available for approximately 30 days.